-
CSCO 2021: In the era of targeted immunotherapy, new thinking on radiotherapy for liver cancer
Time of Update: 2021-10-10
A single high-dose radiation irradiation promotes the polarization of surrounding macrophages to the tumor suppressor M1 type, thereby increasing the immune effect after radiotherapy .
A single high-dose radiation irradiation promotes the polarization of surrounding macrophages to the tumor suppressor M1 type, thereby increasing the immune effect after radiotherapy .
-
Ruguang was born, in the name of the mountain, cracked the code of the otuzumab literature and played the life movement of Chinese FL patients!
Time of Update: 2021-10-10
The emergence of a new type of humanized glycosylation modified type II anti-CD20 mAb-Otuzumab has brought changes in the treatment of FL patients .
A number of studies have shown that otuzumab significantly improves the efficacy of FL patients and brings new hope for the treatment of FL patients .
-
Sub-Journal of Nature: Why do some people get lung cancer without smoking?
Time of Update: 2021-10-10
The results show that the tumor genomes of most lung cancer patients without smoking history have mutations related to the damage of endogenous processes (that is, natural processes that occur in the body).
-
Professor Ying Zhitao has an insightful eye to identify patients, and a clever treatment of disease-CAR-T patients are screened skillfully, and complicated diseases are managed strictly
Time of Update: 2021-10-10
In the process of commercial application of CAR-T cells after the market, Professor Ying Zhitao needs to consider many factors in the selection of patients, mainly including the following aspects: age factor CAR-T treatment-related clinical research adopts the age of the enrolled patients In accordance with strict standards, the ages of patients enrolled in key clinical studies are all less than 80 years old .
-
Clin Cancer Res: New immunotherapy is out!
Time of Update: 2021-10-10
The relevant research results were published under the title "Memory-like Differentiation Enhances NK Cell Responses to Melanoma" In the journal "Clinical Cancer Research" .
Therefore, in this new study, the researchers tested the therapeutic effect of melanoma patients after NK cells were differentiated into memory-like NK cells .
-
Cancers: Survival benefits of EGFR/ALK-negative advanced NSCLC patients after first-line immunotherapy is approved: data from real-world studies
Time of Update: 2021-10-10
Studies have shown that the approval of Immune Checkpoint Inhibitors (ICI) significantly improves the OS of patients with EGFR/ALK-negative advanced NSCLC .
Studies have shown that the approval of Immune Checkpoint Inhibitors (ICI) significantly improves the OS of patients with EGFR/ALK-negative advanced NSCLC .
-
Why does a high-fat diet promote cancer?
Time of Update: 2021-10-10
Although several strategies that cancer uses to evade the immune system have been well-studied, however, scientists know very little about how diet affects tumor immune recognition by intestinal stem cells .
-
J Thorac Oncol: Comprehensive analysis of the prognostic value of TP53 and KEAP1 mutations in non-small cell lung cancer (NSCLC)
Time of Update: 2021-10-10
For local patients (stage I-IIIA)TP53 mutation is significantly related to male, squamous tissue, wild-type status of EGFR, KRAS and ALK/ROS, and NFE2L2 mutation .
-
Br J Cancer: Drinking too much, the risk of breast cancer is high
Time of Update: 2021-10-10
In this study, the researchers aimed to compare the effects of different drinking trajectories in women's life on the occurrence and development of breast cancer .
-
Front Oncol: The effect of partial ureterectomy + adjuvant radiotherapy for distal ureteral urothelial carcinoma (UC)
Time of Update: 2021-10-10
The study showed that for patients with T3 or G3 distal ureteral urothelial carcinoma, compared with simple partial ureterectomy, adjuvant radiotherapy can significantly prolong the recurrence-free survival .
-
Eur J Cancer: The efficacy of arterial chemoembolization with cisplatin or epirubicin in the treatment of liver cancer
Time of Update: 2021-10-10
In the phase 2 study, the disease control rate of the cisplatin group (91.
Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial .
-
Front Oncol: FOLFOX regimen hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib improves the prognosis of advanced hepatocellular carcinoma compared with HAIC alone
Time of Update: 2021-10-10
In 2018, a large retrospective study showed that compared with sorafenib, hepatic arterial infusion chemotherapy (HAIC) based on oxaliplatin, fluorouracil, and leucovorin (FOLFOX) can significantly improve the treatment of advanced HCC Survival (median OS 14.
-
What are the new developments and future development directions of the second-line treatment of gastric cancer?
Time of Update: 2021-10-10
At the 2021 Chinese Society of Clinical Oncology (CSCO) annual meeting, the results of the RAINBOW-Asia Chinese population study were announced, adding new medical evidence for the treatment of advanced gastric cancer in China .
-
Liver Cnacer: Comparison of the efficacy of laparoscopic liver resection versus percutaneous radiofrequency ablation in the treatment of small liver cancer
Time of Update: 2021-10-10
Similarly, the LTP of the following tumors treated by LLR was significantly lower than that of p-RFA: subcapsular (3-year cumulative LTP incidence: 1.
Similarly, the LTP of the following tumors treated by LLR was significantly lower than that of p-RFA: subcapsular (3-year cumulative LTP incidence: 1.
-
Three strategies to reduce the immunogenicity of CAR-T
Time of Update: 2021-10-10
Therefore, strategies such as humanization, ligand receptor domain replacement, and spacer mutations to reduce the immunogenicity of CAR have begun to be used in CAR-T design.
-
Molecular Cancer Huazhong University of Science and Technology Tong Qiangsong/Zheng Liduan discovered potential therapeutic targets for neuroblastoma
Time of Update: 2021-10-10
On September 27, 2021, Tong Qiangsong and Zheng Liduan of Huazhong University of Science and Technology jointly published a research paper entitled "p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation" in Molecular Cancer (IF=27.
-
Express delivery of cervical cancer patients reduces the risk of death by 31%, PD-1 inhibitors are eligible for FDA priority review
Time of Update: 2021-10-10
▎Editor of WuXi AppTec's content team On September 28, 2021, Regeneron announced that the US FDA has granted the company and Sanofi the PD-1 inhibitor Libtayo (cemiplimab) as a supplementary bio The product license application (sBLA) priority review qualification is used to treat patients with recurrent/metastatic cervical cancer who have progressed during or after chemotherapy .
-
Experts comment on Nat Nanotechnol Li Yaping/Zhang Pengcheng's team to develop epigenetic regulation nanovesicles for tumor immunotherapy
Time of Update: 2021-10-10
This research opens up new directions for the "precise delivery + intelligent drug release integration" technology to regulate epigenetics, overcome immune tolerance, and improve tumor immunotherapy.
-
Prostate Cancer PD: What effect does enzalutamide have on the fatigue of prostate cancer patients?
Time of Update: 2021-10-10
Recently, researchers from Belgium published an article in "Prostate Cancer PD", using four enzalutamide-placebo controlled trials (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVALIL (NCT01212991) and AFFIRM (NCT00974311)) The results reported by patients in the medium, assessing the effect of enzalutamide on patient-reported fatigue .
-
Front Oncol: A real-world, multi-center, observational retrospective study of Durvalumab maintenance therapy after concurrent or continuous radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer
Time of Update: 2021-10-10
For unresectable stage III non-small cell lung cancer ( NSCLC ), the standard treatment is maintenance therapy with PD-L1 inhibitors (durvalumab) in patients who respond after radiotherapy and chemotherapy (CRT) .
